Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy.
gastroesophageal cancer
neoadjuvant chemotherapy
prognosis
systemic immune-inflammation index
tumor regression grade
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
13
10
2021
accepted:
06
04
2022
pubmed:
11
5
2022
medline:
20
1
2023
entrez:
10
5
2022
Statut:
ppublish
Résumé
Systemic inflammation has been associated with chemoresistance and prognosis in solid tumors. Systemic immune-inflammation index (SII) is a novel marker derived from complete blood count. We investigated whether differences between SIIs measured before and after neoadjuvant chemotherapy (NACT) are associated with tumor regression grade (TRG) and survival in gastric and gastroesophageal junction (GEJ) cancer patients. Records of gastric and GEJ cancer patients treated with NACT in two centers were evaluated retrospectively. Patients were categorized according to difference between pre- and post-NACT SII values (ΔSII). Association between clinicopathological factors and TRG was analyzed using logistic regression method. Predictors of disease-free and overall survival (DFS and OS) were determined with Cox regression models. The study included 140 patients. Patients with ΔSII<0 were more likely to achieve TRG 0/1 (45.2% vs. 19.1%, p = 0.003) and ΔSII<0 was an independent predictor of TRG 0/1 (OR = 6.05, p<0.001). DFS and OS of patients with ΔSII<0 were also significantly longer (p = 0.031 and p = 0.006, respectively). After adjustment for other variables, ΔSII≥0 was an independent prognostic factor for OS (Hazard ratio (HR) = 2.13, p = 0.008). Changes in SII, which is a low-cost and easily accessible marker, may be used to estimate prognosis, individualize postoperative treatment and optimize surveillance in gastric and GEJ cancer patients treated with NACT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104-112Informations de copyright
© 2022 John Wiley & Sons Australia, Ltd.
Références
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics ort he year 2020: An overview. Int J Cancer. 2021 Apr 5. https://doi.org/10.1002/ijc.33588
Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v38-v49. https://doi.org/10.1093/annonc/mdw350
Tomasello G, Petrelli F, Ghidini M, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607-1616. https://doi.org/10.1016/j.ejso.2017.03.001
Hirahara N, Matsubara T, Fujii Y, et al. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget. 2020;11(27):2625-2635. https://doi.org/10.18632/oncotarget.27653
Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer. 2021;21(1):569. https://doi.org/10.1186/s12885-021-08124-9
Li X, Lin H, Ouyang R, Yang Y, Peng J. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis. Biosci Rep. 2021;41(8):BSR20204401. https://doi.org/10.1042/BSR20204401
Rajwa P, Schuettfort VM, D'Andrea D, et al. Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urol Oncol. 2021;39(11):785.e19-785.e27. https://doi.org/10.1016/j.urolonc.2021.05.002
Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 2017;9:849-867. https://doi.org/10.2147/CMAR.S151026
Inoue H, Kosuga T, Kubota T, et al. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol. 2021;19(1):173. https://doi.org/10.1186/s12957-021-02286-3
Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141-6. https://doi.org/10.1111/j.1365-2559.2005.02176.x
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. https://doi.org/10.1016/j.cell.2010.01.025
Li X, Dai D, Chen B, Tang H, Xie X, Wei W. The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer. 2018;9(5):861-871. https://doi.org/10.7150/jca.23367
Chae S, Kang KM, Kim HJ, et al. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol. 2018;25(2):e113-e119. https://doi.org/10.3747/co.25.3888
Dong J, Sun Q, Pan Y, Lu N, Han X, Zhou Q. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. BMC Cancer. 2021;21(1):700. https://doi.org/10.1186/s12885-021-08458-4
Wang Y, Chen L, Zhang B, et al. Pretreatment Inflammatory-Nutritional Biomarkers Predict Responses to Neoadjuvant Chemoradiotherapy and Survival in Locally Advanced Rectal Cancer. Front Oncol. 2021;11:639909. https://doi.org/10.3389/fonc.2021.639909
Imyanitov EN, Yanus GA. Neoadjuvant therapy: theoretical, biological and medical consideration. Chin Clin Oncol. 2018;7(6):55. https://doi.org/10.21037/cco.2018.09.05
Goto W, Kashiwagi S, Asano Y, et al. Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. ESMO Open. 2018;3(6):e000305. https://doi.org/10.1136/esmoopen-2017-000305
Dan J, Tan J, Huang J, et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer. 2020;27(5):982-988. https://doi.org/10.1007/s12282-020-01096-x
Blackham AU, Greenleaf E, Yamamoto M, et al. Tumor regression grade in gastric cancer: Predictors and impact on outcome. J Surg Oncol. 2016;114(4):434-439. https://doi.org/10.1002/jso.24307
Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol. 2012;19(6):1936-1943. https://doi.org/10.1245/s10434-011-2165-6
Tong Y, Zhu Y, Zhao Y, Shan Z, Zhang J, Liu D. Tumor regression grade predicts survival in locally advanced gastric adenocarcinoma patients with lymph node metastasis. Gastroenterol Res Pract. 2020;2020:3435673. https://doi.org/10.1155/2020/3435673
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381-75388. https://doi.org/10.18632/oncotarget.18856
Chen HC, Lin HC, Liu CY, et al. Neutrophil elastase induces IL-8 synthesis by lung epithelial cells via the mitogen-activated protein kinase pathway. J Biomed Sci. 2004;11(1):49-58. https://doi.org/10.1007/BF02256548
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576-90. https://doi.org/10.1016/j.ccr.2011.09.009
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44. https://doi.org/10.1038/nature07205
Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: A meta-analysis. Front Oncol. 2021;11:537140. https://doi.org/10.3389/fonc.2021.537140
Lin JX, Wang ZK, Huang YQ, et al. Dynamic changes in pre- and postoperative levels of inflammatory markers and their effects on the prognosis of patients with gastric cancer. J Gastrointest Surg. 2021;25(2):387-396. https://doi.org/10.1007/s11605-020-04523-8
Wang F, Liu ZY, Xia YY, et al. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. Oncol Lett. 2015;10(6):3411-3418. https://doi.org/10.3892/ol.2015.3783
Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol. 2020;85(2):265-272. https://doi.org/10.1007/s00280-019-04023-w
Li Z, Li S, Ying X, et al. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer. 2020;23(3):540-549. https://doi.org/10.1007/s10120-019-01027-6
Xu W, Ma Q, Wang L, et al. Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative Chemotherapy. Front Oncol. 2021;11:607640. https://doi.org/10.3389/fonc.2021.607640
Li Z, Wang Y, Shan F, et al. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer. 2018;21(6):977-987. https://doi.org/10.1007/s10120-018-0830-1
Adachi Y, Yasuda K, Inomata M, Shiraishi N, Kitano S, Sugimachi K. Clinicopathologic study of early-stage mucinous gastric carcinoma. Cancer. 2001;91(4):698-703.
Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2):e88907. https://doi.org/10.1371/journal.pone.0088907
Choi AR, Park JC, Kim JH, et al. High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol. 2013;19(32):5302-8. https://doi.org/10.3748/wjg.v19.i32.5302